29 July 2015 – PLC would like to recognize Adapt Pharma and Lightlake Therapeutics, partners developing a naloxone-based nasal spray for opioid overdose reversal, on their recent NDA submission to the US FDA. PLC has worked with both Adapt and Lightlake on their US regulatory filings and submitted the NARCAN® (naloxone hydrochloride) nasal spray NDA for expedited review on Adapt’s behalf.
Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Submits NDA to FDA for Narcan (naloxone) Nasal Spray
